CJC-1295
Modified GHRH analog
CJC-1295-type compounds are studied through the GHRH receptor and GH/IGF-1 axis.
Open CJC-1295 hub →Research comparison
CJC-1295 vs Ipamorelin
A research-focused comparison of compound identity, research mechanism, evidence maturity and documentation. This page does not provide dosing or medical guidance.
VS
Ipamorelin
Growth-hormone secretagogue pentapeptide
Ipamorelin is studied as a ghrelin-receptor/GHS-R agonist and growth-hormone secretagogue.
Open Ipamorelin hub →Key distinction
What is the main difference?
They act through different upstream receptor systems: GHRH-receptor signaling versus ghrelin-receptor signaling.
Research overlap
Where do the research areas overlap?
They are often discussed together because both can influence GH-release research, but they are not the same mechanism.
Evidence context
How should the evidence be compared?
Research interpretation depends on exact CJC molecular form, including whether DAC is present.
Use primary sources.Compare model type, study population, route of administration, endpoint and molecular form before drawing conclusions across compounds.
Independent literature
Research both compounds independently
FAQ
CJC-1295 vs Ipamorelin FAQ
Are CJC-1295 and Ipamorelin the same compound?
No. They have distinct molecular identities and should be researched and documented separately.
Which one has stronger evidence?
Evidence strength depends on the specific research question. Compare the number and quality of human studies, preclinical studies, study design and whether the exact molecular form matches the compound being discussed.
Can findings from one be applied to the other?
Not automatically. Findings should remain tied to the compound, model, dose, route and endpoint used in the original study.
Where can I verify NPC product documentation?
Use Northern Peptide Collective's COA Verification page and match analytical documentation to the exact product lot where available.